{"generic":"Chorionic Gonadotropin Alfa, Recombinant","drugs":["Chorionic Gonadotropin Alfa, Recombinant","Ovidrel"],"mono":{"0":{"id":"926015-s-0","title":"Generic Names","mono":"Chorionic Gonadotropin Alfa, Recombinant"},"1":{"id":"926015-s-1","title":"Dosing and Indications","sub":{"0":{"id":"926015-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Assisted reproductive technology:<\/b> 250 mcg SUBQ for a single dose, given 1 day following the last dose of follicle stimulating agent; administer only after adequate follicular development is indicated by serum estradiol and vaginal ultrasonography; withhold if excessive ovarian response (multiple follicular development, clinically significant ovarian enlargement, or excessive estradiol production)<\/li><li><b>Ovulation induction:<\/b> 250 mcg SUBQ for a single dose, given 1 day following the last dose of follicle stimulating agent; administer only after adequate follicular development is indicated by serum estradiol and vaginal ultrasonography; withhold if excessive ovarian response (multiple follicular development, clinically significant ovarian enlargement, or excessive estradiol production)<\/li><\/ul>"},"1":{"id":"926015-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in pediatric patients "},"3":{"id":"926015-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Assisted reproductive technology<\/li><li>Ovulation induction<\/li><\/ul>"}}},"3":{"id":"926015-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926015-s-3-9","title":"Contraindications","mono":"<ul><li>abnormal uterine bleeding of undetermined origin<\/li><li>hypersensitivity to hCG preparations or any component of the product<\/li><li>ovarian cyst or enlargement of undetermined origin<\/li><li>pregnancy<\/li><li>primary ovarian failure<\/li><li>sex hormone-dependent tumors of the reproductive tract and accessory organs<\/li><li>uncontrolled organic intracranial lesion, such as a pituitary tumor<\/li><li>uncontrolled thyroid or adrenal dysfunction<\/li><\/ul>"},{"id":"926015-s-3-10","title":"Precautions","mono":"<ul><li>ALT elevations have been reported<\/li><li>arterial thromboembolism may occur<\/li><li>multiple births have been reported; advise patient of potential risk<\/li><li>ovarian enlargement may occur; do not administer hCG if ovaries are abnormally enlarged on last day of follicle-stimulating hormone (FSH) therapy to reduce risk of ovarian hyperstimulation syndrome<\/li><li>ovarian hyperstimulation syndrome (OHSS), sometimes severe, has been reported with or without pulmonary or vascular complications; follow patients for at least 2 weeks after hCG; if evidence of OHSS occurs prior to hCG, withhold therapy; if severe OHSS occurs, discontinue hCG and hospitalize patient<\/li><li>prior medical or family history of thromboembolic event risk factors<\/li><\/ul>"},{"id":"926015-s-3-11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"926015-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"926015-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site pain (7.6% to 8.1%)<\/li><li><b>Reproductive:<\/b>Multiple birth (13.3% to 30.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Thromboembolic disorder<\/li><li><b>Reproductive:<\/b>Ovarian hyperstimulation syndrome (3%)<\/li><\/ul>"},"6":{"id":"926015-s-6","title":"Drug Name Info","sub":{"0":{"id":"926015-s-6-17","title":"US Trade Names","mono":"Ovidrel<br\/>"},"2":{"id":"926015-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Gonadotropin<\/li><\/ul>"},"3":{"id":"926015-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"926015-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"926015-s-7","title":"Mechanism Of Action","mono":"Recombinant chorionic gonadotropin alfa, an analog of luteinizing hormone (LH), stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle; it has similar properties to those of placental and human pregnancy urine-derived hCG.<br\/>"},"8":{"id":"926015-s-8","title":"Pharmacokinetics","sub":{"0":{"id":"926015-s-8-23","title":"Absorption","mono":"<ul><li>Tmax (median), Subcutaneous: 24 hours (range, 12 to 24 hours)<\/li><li>Bioavailability, Subcutaneous: 40%<\/li><\/ul>"},"1":{"id":"926015-s-8-24","title":"Distribution","mono":"Vd: 5.9 +\/- 1 L <br\/>"},"3":{"id":"926015-s-8-26","title":"Excretion","mono":"<ul><li>Renal: 10%<\/li><li>Total body clearance: 0.29 +\/- 0.04 L\/hr (IV)<\/li><\/ul>"},"4":{"id":"926015-s-8-27","title":"Elimination Half Life","mono":"29 +\/- 6 hours (SUBQ) <br\/>"}}},"9":{"id":"926015-s-9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/>for single SUBQ administration only; discard unused portion <br\/>"},"10":{"id":"926015-s-10","title":"Monitoring","mono":"<ul><li>serum progesterone level; increase is clinical confirmation of ovulation<\/li><li>increase in basal body temperature is indicative of ovulation<\/li><li>menstruation following increase in basal body temperature is indicative of ovulation<\/li><li>serum estradiol levels and transvaginal ultrasound regularly during therapy to minimize risk of ovarian overstimulation<\/li><li>laboratory values and signs\/symptoms of development of ovarian hyperstimulation syndrome (eg, severe pelvic pain, weight gain, electrolyte abnormalities, ascites, thromboembolic events, liver function test abnormalities) for at least 2 weeks after hCG administration<\/li><\/ul>"},"11":{"id":"926015-s-11","title":"How Supplied","mono":"<b>Ovidrel<\/b><br\/>Subcutaneous Solution: 0.25 MG\/0.5 ML<br\/>"},"13":{"id":"926015-s-13","title":"Clinical Teaching","mono":"<ul><li>Drug may cause nausea, vomiting, injection site reactions, ovarian cysts, and abdominal pain or discomfort.<\/li><li>Advise patient to report signs\/symptoms of ovarian enlargement or hyperstimulation syndrome (abdominal bloating\/distension, lower abdominal pain, severe pelvic pain, dyspnea, oliguria).<\/li><li>Instruct patient to report signs\/symptoms of thromboembolism.<\/li><li>If self-administered, teach patient proper technique and placement of injections.<\/li><\/ul>"}}}